135124-70-8

Basic information

• Product Name: 3-(Aminomethyl)-5-bromopyridine 97%
• Synonyms: 3-(Aminomethyl)-5-bromopyridine 97%;(5-BROMO-3-PYRIDINYL)METHYLAMINE;5-BROMO-3-PYRIDINEMETHANAMINE;5-BROMO-3-PYRIDINEMETHYLAMINE;3-(Aminomethyl)-5-bromopyridine;3-(Aminomethyl)-5-bromopyridine 95+%;(5-Bromopyridin-3-yl)methylamine;(5-Bromopyridin-3-yl)methylamine, alpha-Amino-5-bromo-3-picoline
• CAS NO: 135124-70-8
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.05
• Product Categories: Building Blocks;Pyridine
• Mol File: 135124-70-8.mol
• Article Data: 48

Chemical Properties

• Boiling Point: 269.4°Cat760mmHg
• Flash Point: 116.7°C
• Appearance: /
• Density: 1.574g/cm³
• Vapor Pressure: 0.00726mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.75±0.29(Predicted)
• CAS DataBase Reference: 3-(Aminomethyl)-5-bromopyridine 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Aminomethyl)-5-bromopyridine 97%(135124-70-8)
• EPA Substance Registry System: 3-(Aminomethyl)-5-bromopyridine 97%(135124-70-8)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 135124-70-8(Hazardous Substances Data)

Usage

General Description

3-(Aminomethyl)-5-bromopyridine 97% is a chemical compound that is 97% pure. It is a derivative of pyridine with a bromine atom at the 5th position and an aminomethyl group at the 3rd position. 3-(Aminomethyl)-5-bromopyridine 97% is often used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It is known for its use in the production of quinolone antibacterial agents and other biologically active compounds. The high purity of this chemical makes it suitable for use in research, development, and manufacturing processes in the pharmaceutical and chemical industries.

InChI:InChI=1/C6H7BrN2/c7-6-1-5(2-8)3-9-4-6/h1,3-4H,2,8H2

Upstream product

• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 145743-86-8 methanesulfonic acid 5-bromo-pyridin-3-ylmethyl ester 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 120277-69-2 5-bromo-pyridin-3-ylmethyl chloride 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 219660-71-6 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione 
• 856212-28-7 3-azidomethyl-5-bromo-pyridine 
• 28733-43-9 5-bromonicotinamide 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 136918-14-4 phthalimide 
• 375854-08-3 3-bromo-5-(N,N-bis-tert-butoxycarbonyl)aminomethylpyridine 

Downstream Products

• 219660-72-7 1-(5-bromopyridin-3-yl)-N-(diphenylmethylene)methanamine 
• 943722-24-5 3-bromo-5-(tert-butoxycarbonyl)aminomethylpyridine 
• 917373-58-1 N-[(5-Bromopyridin-3-yl)methyl]-10-[(2'-methoxy-1,1'-biphenyl-4-yl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-3-carboxamide 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR PARASITE CONTROL

The present invention relates in its broadest aspect to a compound of Formula I as provided herein, formulations comprising such a compound and corresponding uses thereof for the reduction of infestation with ectoparasites, in particular ectoparasites of the insect class, including fleas and mosquitoes and/or ectoparasites of the arachnid class, including ticks and mites, etc. Also provided herein are methods for preparing the formulations of the invention and methods for controlling ectoparasites using the compounds and/or formulations provided herein.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.